Michael S. Mathisen
About
Michael S. Mathisen is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Genetics.
According to data from OpenAlex, Michael S. Mathisen has authored 22 papers receiving a total of 475 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Hematology, 7 papers in Public Health, Environmental and Occupational Health and 6 papers in Genetics. Recurrent topics in Michael S. Mathisen's work include Acute Myeloid Leukemia Research (8 papers), Acute Lymphoblastic Leukemia research (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Michael S. Mathisen is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Acute Lymphoblastic Leukemia research (7 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Michael S. Mathisen collaborates with scholars based in United States, Switzerland and Canada. Michael S. Mathisen's co-authors include Hagop M. Kantarjian, Tito Fojo, Leonard A. Zwelling, Elias Jabbour, Jörge E. Cortes, Jagpreet Chhatwal, Deborah McCue, Dimitrios P. Kontoyiannis, Emily Wang and Dimitrios Farmakiotis and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.
In The Last Decade
Michael S. Mathisen
22 papers receiving 462 citations
Peers
Michael S. Mathisen
Hira Mian Canada
Richa Chauhan India
Roman M. Shapiro United States
P.C. Huijgens Netherlands
Nikita Mehra India
Sebastian Gonzalez‐McQuire Switzerland
Bendt Nielsen Denmark
Michael Keng United States
Ash Bullement United Kingdom
Victor Olsavszky Germany
Citations per year, relative to Michael S. Mathisen Michael S. Mathisen (= 1×)
peers
Hira Mian
Countries citing papers authored by Michael S. Mathisen
Since
Specialization
Citations
This map shows the geographic impact of Michael S. Mathisen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael S. Mathisen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael S. Mathisen more than expected).
Fields of papers citing papers by Michael S. Mathisen
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Michael S. Mathisen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael S. Mathisen. The network helps show where Michael S. Mathisen may publish in the future.
Co-authorship network of co-authors of Michael S. Mathisen
This figure shows the co-authorship network connecting the top 25 collaborators of Michael S. Mathisen. A scholar is included among the top collaborators of Michael S. Mathisen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael S. Mathisen. Michael S. Mathisen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Skoulidis, Ferdinandos, Kristof Cuppens, Adrian G. Sacher, et al.. (2024). Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). TPS8651–TPS8651.
2.
Dziadziuszko, Rafał, Nir Peled, Tony Mok, et al.. (2023). High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial. Współczesna Onkologia. 27(4). 217–223.
3.
Peters, Solange, Shirish M. Gadgeel, Tony Mok, et al.. (2022). Efficacy/safety of entrectinib in patients (pts) with ROS1-positive (ROS1+) advanced/metastatic NSCLC from the Blood First Assay Screening Trial (BFAST).. Journal of Clinical Oncology. 40(17_suppl). LBA9023–LBA9023.
4.
Dziadziuszko, Rafał, Xiao Li, Eric Anderson, et al.. (2021). Clinicogenomic real-world data analysis of patients (pts) with KRAS G12C-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).. Journal of Clinical Oncology. 39(15_suppl). 9023–9023.
5.
Zhang, Weijiang, Michael S. Mathisen, Grant R. Goodman, et al.. (2020). Effect of Itraconazole, a Potent CYP3A4 Inhibitor, on the Steady‐State Pharmacokinetics of Vemurafenib in Patients With BRAFV600 Mutation–Positive Malignancies. Clinical Pharmacology in Drug Development. 10(1). 39–45.
6.
Kantarjian, Hagop M., Michael S. Mathisen, & Jeffrey H. Lipton. (2015). Having “Skin in the Game” and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs. JAMA Oncology. 1(6). 729–729.
7.
Chhatwal, Jagpreet, Michael S. Mathisen, & Hagop M. Kantarjian. (2015). Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer. 121(19). 3372–3379.
8.
Wang, Emily, Dimitrios Farmakiotis, Deborah McCue, et al.. (2015). The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. Journal of Antimicrobial Chemotherapy. 70(8). 2362–2368.
9.
Mathisen, Michael S., Hagop M. Kantarjian, Jörge E. Cortes, & Elias Jabbour. (2014). Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia. Blood Reviews. 28(5). 179–187.
10.
Mathisen, Michael S., Hagop M. Kantarjian, & Elias Jabbour. (2013). Emerging drugs for acute lymphocytic leukemia. Expert Opinion on Emerging Drugs. 19(1). 37–50.
11.
Jabbour, Elias, Naval Daver, Richard E. Champlin, et al.. (2013). Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high‐dose cytarabine‐based induction chemotherapy. American Journal of Hematology. 89(4). 395–398.
12.
Mathisen, Michael S., Hagop M. Kantarjian, Deborah A. Thomas, Susan O’Brien, & Elias Jabbour. (2013). Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates. Leukemia & lymphoma. 54(12). 2592–2600.
13.
Kantarjian, Hagop M., Tito Fojo, Michael S. Mathisen, & Leonard A. Zwelling. (2013). Cancer Drugs in the United States: Justum Pretium—The Just Price. Journal of Clinical Oncology. 31(28). 3600–3604.
14.
Mathisen, Michael S., Hagop M. Kantarjian, Elias Jabbour, et al.. (2012). Clofarabine Does Not Negatively Impact the Outcomes of Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Clinical Lymphoma Myeloma & Leukemia. 13(2). 139–143.
15.
Jabbour, Elias, et al.. (2012). 10 Years of Progress in Chronic Myelogenous Leukemia. Journal of the National Comprehensive Cancer Network. 10(9). 1049–1053.
16.
Mathisen, Michael S., Hagop M. Kantarjian, Farhad Ravandi, et al.. (2012). Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML). Blood. 120(21). 3610–3610.
17.
Ohanian, Maro, Gautam Borthakur, Alfonso Quintás‐Cardama, et al.. (2012). Ocular Granulocytic Sarcoma: A Case Report and Literature Review of Ocular Extramedullary Acute Myeloid Leukemia. Clinical Lymphoma Myeloma & Leukemia. 13(1). 93–96.
18.
Jabbour, Elias, Michael S. Mathisen, Guillermo Garcia‐Manero, et al.. (2012). Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: A retrospective case–control study. American Journal of Hematology. 88(3). 198–200.
19.
Mathisen, Michael S., Hagop M. Kantarjian, Stefan Faderl, et al.. (2012). Interim results of a phase I/II randomized study of clofarabine, idarubicin, and cytarabine (CIA) versus fludarabine, idarubicin, and cytarabine (FIA) for newly diagnosed or relapsed patients (pts) with acute myeloid leukemia (AML).. Journal of Clinical Oncology. 30(15_suppl). 6607–6607.
20.
Mathisen, Michael S., Susan O’Brien, Deborah A. Thomas, et al.. (2011). Role of Tyrosine Kinase Inhibitors in the Management of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia. Current Hematologic Malignancy Reports. 6(3). 187–194.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hira Mian Breakdown of academic impact, for papers by Richa Chauhan Breakdown of academic impact, for papers by Roman M. Shapiro Breakdown of academic impact, for papers by P.C. Huijgens Breakdown of academic impact, for papers by Nikita Mehra Breakdown of academic impact, for papers by Sebastian Gonzalez‐McQuire Breakdown of academic impact, for papers by Bendt Nielsen Breakdown of academic impact, for papers by Michael Keng Breakdown of academic impact, for papers by Ash Bullement Breakdown of academic impact, for papers by Victor Olsavszky